Compare Baxter International Inc (BAX) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Infosys Limited — how do they compare? Baxter International Inc trades at $26.85 (market cap $14.27B), while Infosys Limited trades at $12.18 (market cap $50.55B). The key difference: Infosys Limited is far larger — about 3.5× Baxter International Inc's market cap, and Infosys Limited pays the higher dividend (4.16%). Which is the better fit depends on your goals.
| BAX | INFY | |
|---|---|---|
Market Cap | $14.27B | $50.55B |
Sector | Health | Technology |
52-Week High | $28.35 | $20.22 |
52-Week Low | $15.80 | $10.49 |
Enterprise Value | $21.79B | $48.30B |
Dividend Yield | 0.14% | 4.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
INFY trades at $12.17, down 3.11% today, with mixed technical signals: a bullish moving average trend but overbought RSI levels. The company reported a Q2 2026 EPS miss but beat in prior quarters, maintaining strong profitability with a 16.37% net margin. Recent news highlights AI collaborations and a CEO transition, while institutional activity shows both buying and selling.
Outlook is cautious due to near-term revenue softness and lowered growth guidance, though solid cash flow and margins provide support. Risks include competitive pressures and macroeconomic headwinds. Analysts are mixed with a consensus price target of $11.05, suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
